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Purpose: To evaluate the negative predictive value (NPV) of ultrasound (US) elastography for 
non-palpable Breast Imaging Reporting and Data System (BI-RADS) category 3 lesions on 
ultrasonography and to determine whether US elastography is helpful in reducing the number of 
BI-RADS category 3 lesions on ultrasonography.
Methods: Two hundred seventy-six consecutive, non-palpable BI-RADS category 3 lesions in 256 
women who underwent US elastography and US-guided core biopsy, and who had at least 12 
months of follow-up data, comprised our study group. The BI-RADS final assessment category 
and elasticity score were prospectively and independently classified. The rate of malignancy and 
NPV according to the elasticity score were analysed. We also investigated whether there was a 
subset of BI-RADS category 3 lesions that were of benign histology but negative on elastography.
Results: Of the 276 non-palpable BI-RADS category 3 lesions, three lesions (1.0%) were finally 
confirmed as ductal carcinomas in situ. No cancers were found in the remaining 273 lesions with 
benign biopsy histology at a mean follow-up of 39.4 months (range, 12 to 72 months). The NPV 
of a negative elasticity score (elasticity score of 1) was 99.3% (165 of 166). If BI-RADS category 
3 lesions showing a negative elasticity score were downgraded to BI-RADS category 2, 60.4% 
(165 of 273) of them with benign histology could have been safely followed without biopsy with 
an increased malignancy rate from 1% (3 of 276) to 1.8% (2 of 110), which is not significantly 
higher (P=0.626).  
Conclusion: US elastography has the potential to reduce the number of BI-RADS category 3 
lesions on ultrasonography.
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Introduction
With the expanded role of screening breast ultrasonography and accumulating clinical experience, the 
American College of Radiology (ACR) has established the Breast Imaging Reporting and Data System US Elastography for BI-RADS Category 3 Lesions
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(BI-RADS) ultrasonography lexicon to standardize terminology 
for description and management recommendations according 
to stratified risks [1]. In the field of mammography screening, it 
has been established that probably benign (BI-RADS category 3) 
lesions having a malignancy rate of less than 2% require short-
term imaging follow-up rather than immediate biopsy [2,3]. 
Although BI-RADS category 3 criteria have been validated for non-
calcified, circumscribed oval masses on both mammography and 
ultrasonography [3,4], there has been no validation for such lesions 
found on ultrasonography. Their incidences on ultrasonography have 
been reported to range from 15.7% to 32.2% [4-7], and their 
malignancy rate from 0% to 2.6% [4-10]. A recent prospective 
study suggested an annual follow-up recommendation rather 
than short-term follow-up for non-palpable BI-RADS category 3 
lesions on ultrasonography based on their low malignancy rate, low 
incidence of suspicious changes at 6-month follow-up, and early 
stage of detected cancers [8].
Another approach to reduce unnecessary short-term follow-ups 
or biopsies and to increase the specificity of supplemental screening 
ultrasonography is the use of ultrasound (US) elastography. US 
elastography has been reported to be useful to distinguish benign 
from malignant lesions [11-18]. Recent studies also have suggested 
that US elastography might be helpful for further characterizing 
lesions with low suspicion and thereby reducing the need for 
biopsies with benign results [6,14-18]. However, to the best of our 
knowledge, there have been few studies regarding the application 
of US elastography in reducing the number of BI-RADS category 
3 lesions [19]. Thus, the aims of this study were to evaluate the 
negative predictive value (NPV) of US elastography for non-palpable 
BI-RADS category 3 lesions on ultrasonography and to determine 
whether US elastography is helpful in reducing the number of BI-
RADS category 3 lesions on ultrasonography.
Materials and Methods
Patients and Breast Masses 
Our institutional review board approved this study, and informed 
consent was obtained from each woman before the biopsy. 
From May 2006 through June 2009, 2,107 consecutive women 
underwent B-mode ultrasonography, US elastography, and a 
subsequent US-guided needle biopsy of 2,527 non-palpable breast 
masses. The inclusion criteria were as follows: (1) non-palpable 
breast lesions classified as BI-RADS category 3 based on B-mode 
ultrasonography, (2) lesions that have undergone US elastography, 
(3) lesions that have undergone US-guided core biopsy, (4) lesions 
that were followed for at least 1 year after US-guided biopsy. Among 
the 2,527 lesions, 299 lesions were classified as BI-RADS category 
3 on B-mode breast ultrasonography in 273 women. Sixteen lesions 
were excluded owing to unavailability of 1-year follow-up data. 
Seven lesions were additionally excluded due to a lesion size larger 
than 30 mm, as sufficient normal tissue around the target lesion 
was needed to obtain adequate strain images [20]. Therefore, the 
size criteria for final inclusion was a lesion of 30 mm or less. A total 
of 276 breast masses (mean size, 9.8 mm; range, 3 to 26 mm) in 
256 women (mean age, 45.6 years; range, 24 to 67 years) were 
included in the final data analysis. Of the 256 women, 231 women 
(90.2%) had no symptoms, 23 women (8.9%) had pain, and two 
women (0.7%) had bilateral milky nipple discharge. These women 
underwent biopsies even without any clinically suspicious features 
due to the request of the woman or the referring clinician.  
B-mode Ultrasonography
B-mode ultrasonography was performed using a 14- to 6-MHz 
linear transducer of a EUB-8500 (Hitachi Medical, Tokyo, Japan) 
ultrasonography system. One of nine radiologists with 1-10 years’ 
experience in performing and interpreting breast ultrasonography 
and mammography performed the ultrasonography after reviewing 
available mammographic images. Of the 256 women, 251 (98.0%) 
had available mammograms at the time of ultrasonography. All 
mammographic findings were correlated with US findings during 
the ultrasonography. Of the 251 mammograms, 1 (0.3%) had an 
almost entirely fatty breast (BI-RADS 1 density), 47 (18.7%) had 
scattered fibroglandular tissue in fatty breasts (BI-RADS 2 density), 
176 (70.1%) had heterogeneously dense breasts (BI-RADS 3 
density), and 27 (10.7%) had extremely dense breasts (BI-RADS 4 
density). Of the 251 mammograms, no abnormality was found in 
167 (66.5%), an asymmetry or a mass was found in 47 (18.7%), 
and microcalcifications with or without a mass or asymmetry 
were found in 37 (14.7%). After a mass was identified on B-mode 
ultrasonography, radial and antiradial scans were performed for 
accurate characterization. The final assessment category of B-mode 
ultrasonography was prospectively determined, and less than 2% 
of the cases were classified in BI-RADS category 3 with expected 
malignancy risk. Regarding the criteria for BI-RADS category 3, a 
solid mass without any suspicious features and showing an oval 
shape, circumscribed margin, parallel orientation, and no posterior 
features or minimal enhancement was considered to be probably 
benign [4]. Clustered microcysts, complicated cysts, or postop scars 
were also considered probably benign [1]. It was recommended that 
those lesions be followed up at 6, 12, and 24 months in our clinical 
practice. However, when referring physicians or patients requested a 
biopsy for the lesions, US-guided core biopsy was performed. Nariya Cho, et al.
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US Elastography  
One of nine radiologists performed US elastography at the time of 
the scheduled biopsy procedure. The mean time interval between 
the previous B-mode ultrasonography  and US elastography was 26 
days (range, 0 to 356 days). There were three cases with an interval 
between the previous B-mode ultrasonography and US elastography 
of more than 180 days, but none of those cases showed a lesion 
size or category change. All of the radiologists had experience with 
more than 100 cases of US elastography, which was obtained using 
a 14- to 16-MHz linear transducer with a EUB-8500 machine, as 
performed in a previous study [13]. A five-point elasticity score 
suggested by a previous study [11] was prospectively classified 
and recorded in the medical records of US-guided core biopsy on 
a picture archiving and communication system as follows. A score 
of 1 indicated uniform strain for the entire hypoechoic lesion (i.e., 
the image of the entire lesion was evenly shaded in green). A score 
of 2 indicated strain in most of the hypoechoic lesion with some 
areas of no strain (i.e., the hypoechoic lesion had a mosaic pattern 
of green and blue). A score of 3 indicated strain at the periphery of 
the hypoechoic lesion with sparing of the centre of the lesion (i.e., 
the peripheral part of the lesion was green, and the central part was 
blue). A score of 4 indicated no strain in the entire hypoechoic lesion 
(i.e., the entire hypoechoic lesion was blue, but its surrounding area 
was green). A score of 5 indicated no strain in the entire hypoechoic 
lesion or in the surrounding area (i.e., both the entire hypoechoic 
lesion and its surrounding area were blue). Immediately after the 
US elastographic examinations, the radiologist performed US-
guided needle biopsy using a 14-gauge automated gun (Pro-Mag 
2.2, Manan Medical Products, Northbrook, IL, USA) or an 11-gauge 
vacuum-assisted device. 
 
Data Analysis
A blinded radiologist who had not performed the conventional 
ultrasound or US elastography analysed the data as follows: first, 
elasticity scores according to the histologic results of 276 lesions 
were tabulated, and the mean elasticity scores according to the 
histological types were calculated. Second, the rate of malignancy, 
sensitivity, specificity, positive predictive value (PPV), and NPV 
according to the elasticity score were analysed. Sensitivity and 
specificity were evaluated with the cut-off value between the 
elasticity scores of 1 and 2 as performed previously to prevent 
a decrease in the sensitivity of US elastography [14]. Lastly, we 
investigated whether a subset of the BI-RADS category 3 lesions 
on B-mode ultrasonography could be downgraded to category 
2 upon the addition of US elastography. The statistical analyses 
were performed using SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA). 
Differences with a P-value of less than 0.05 were considered 
significant.
Results
Elasticity Scores According to Histopathology
Of the 276 lesions, three lesions (1.0%) were malignant and 273 
(98.9%) were benign, which was confirmed by 14-gauge core 
needle biopsy (n=224), 11-gauge vacuum-assisted biopsy (n=42), 
or US-guided surgical excision (n=7). All 273 benign lesions were 
followed for a mean of 39.4 months (range, 12 to 72 months), 
and their lesion stability was confirmed. Fifty-six of the 273 benign 
lesions (20.5%) were followed for 12-23 months. The malignant 
lesions comprised three ductal carcinomas in situ (DCISs). Two of 
them were initially reported to be atypical ductal hyperplasia (ADH) 
at core biopsy and were confirmed as DCIS by subsequent surgical 
excision. Regarding the benign papillomas, there were 5 intraductal 
papillomas, and all of the papillomas were confirmed to be benign 
by surgical excision (n=3) or by their stability for at least 3 years 
of follow-up (n=2). The mean lesion size, defined as the maximal 
diameter measured on ultrasonography, of the malignant masses 
was 14.3±9.7 mm (range, 6 to 25 mm), and the mean size of the 
benign masses was 9.8±4.9 mm (range, 3 to 26 mm).
The most common histologic findings of 276 lesions with BI-RADS 
category 3 were a fibrocystic change (111, 40.2%) followed by a 
fibroadenoma (87, 31.5%) (Table 1). An elasticity score of 1 (60.1%, 
165 of 276) was the most common score for benign lesions (Fig. 
1), whereas each of the three malignant masses showed elasticity 
scores of 1, 2, and 5 (Table 2).
Rate of Malignancy According to the Elasticity Score
The overall malignancy rate of BI-RADS category 3 lesions was 1.0% 
(3 of 276). The rate of malignancy according to the elasticity score 
was 0.6% (1 of 166) for a score of 1, 1.0% (1 of 92) for a score of 
2, 0% (0 of 17) for a score of 3, and 100% (1 of 1) for a score of 5. 
No lesion showed an elasticity score of 4. When a cut-off value was 
defined as between an elasticity score of 1 vs. 2, 3, 4, or 5, and the 
elasticity score of 1 was defined as negative and the elasticity score 
of 2, 3, 4, or 5 as positive, US elastography showed a sensitivity of 
66.6% (2 of 3), specificity of 60.4% (165 of 273), PPV of 1.8% (2 
of 110), and NPV of 99.3% (165 of 166). 
   
Downgrading from BI-RADS Category 3 to Category 2 
Based on US Elastography
There were three cancer cases with 276 BI-RADS category 3 lesions. 
One of each showed an elasticity score of 1, 2, and 5 (Tables 1, 2; 
Figs. 2, 3). Thus, if BI-RADS category 3 lesions showing an elasticity 
score of 1 were downgraded to BI-RADS category 2, 60.4% (165 of US Elastography for BI-RADS Category 3 Lesions
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Table 2. Characteristics of the three malignant BI-RADS category 3 lesions
No. Age (yr) Size (mm) E-score Histology at core needle biopsy Histology at surgery Mammographic findings
1 48 25 1 Atypical ductal hyperplasia 4.5 cm, DCIS, cribriform and 
papillary type, low grade
Asymmetry
2 39 12 5 Atypical ductal hyperplasia 
involving papilloma
1.5 cm, DCIS, papillary type, 
low grade
Negative
3 49 6 2 DCIS, low grade 1.0 cm, mixed DCIS and LCIS  Negative
BI-RADS, Breast Imaging Reporting and Data System; E-score, elasticity score; DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ.
Fig. 1. A 50-year-old woman with a Breast Imaging Reporting and Data System (BI-RADS) category 3 lesion on supplemental screening 
ultrasonography. 
A. Transverse B-mode ultrasonogram shows an 11-mm, oval, circumscribed mass (arrows). B. Ultrasound (US) elastographic image shows 
the entire mass as green, indicating an elasticity score of 1. US-guided core biopsy revealed a fibrocystic change. Thirty-six month follow-up 
ultrasonography showed the lesion was not changed (not shown). 
A B
Table 1. Histopatholoy of BI-RADS category 3 lesions according to the elasticity score
Histology
Elasticity score
Mean±SD 1 2 3 4 5 Total
Fibrocystic change 1.37±0.56 74 (26.8) 33 (11.9) 4 (1.4) 0 0 111 (40.2)
Fibroadenoma 1.55±0.66 47 (17.0) 32 (11.5) 8 (2.8) 0 0 87 (31.5)
Intraductal papilloma 1.60±0.89 3 (1.0) 1 (0.3) 1 (0.3) 0 0 5 (1.8)
Usual ductal epithelial hyperplasia 1.67±0.62 6 (2.1) 8 (2.8) 1 (0.3) 0 0 15 (5.4)
Adenosis 1.50±0.67 7 (2.5) 4 (1.4) 1 (0.3) 0 0 12 (4.3)
Granuloma 1.0 1 (0.3) 0 0 0 0 1 (0.3)
Fibrosis 1.50±0.71 1 (0.3) 1 (0.3) 0 0 0 2 (0.7)
Fat necrosis 1.67±0.58 1 (0.3) 2 (0.7) 0 0 0 3 (1.0)
Nonspecific benign disease
a) 1.39±0.60 25 (9.0) 10 (3.6) 2 (0.7) 0 0 37 (13.4)
Cancer 2.67±2.08 1 (0.3) 1 (0.3) 0 0 1 (0.3) 3 (1.0)
Total 166 (60.1) 92 (33.3) 17 (6.1) 0 1 (0.3) 276 (100)
Values are presented as number (%) of all 276 lesions.
BI-RADS, Breast Imaging Reporting and Data System. 
a)Nonspecific benign disease includes adipose tissue, ductal dilation, or benign mammopathy.Nariya Cho, et al.
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273) of BI-RADS category 3 lesions with benign histology could have 
been downgraded, without a significantly increased malignancy rate, 
that is, from 1% (3 of 276) to 1.8% (2 of 110; P=0.626).
Discussion
According to our study, US elastography has the potential in reducing 
the number of BI-RADS category 3 lesions on ultrasonography. 
When lesions with BI-RADS category 3 showing a negative elasticity 
score were downgraded to category 2, 60.4% (165 of 273) of the 
BI-RADS category 3 lesions with benign histology could have been 
reduced without a significantly increased malignancy rate from 1% 
(3 of 276) to 1.8% (2 of 110; P=0.626), leading to substantial cost 
savings and reduced morbidity. 
Our results are similar to those of a recent study using shear-
wave elastography in the characterization of BI-RADS category 3 
lesions [19]. They found that the criterion of an E-color of ‘black to 
dark blue’ allowed for the downgrading of 36.3% (110 of 303) of 
the benign masses without a significant increase in the malignancy 
rate, that is, from 2.6% to 4.1% [19]. However, controversy remains 
Fig. 2. A 48-year-old woman with a Breast Imaging Reporting and Data System (BI-RADS) category 3 lesion on supplemental screening 
ultrasonography. 
A. Longitudinal B-mode ultrasonogram shows a 25-mm, isoechoic, microlobulated mass (arrows). B. Ultrasound (US) elastographic image 
shows the entire lesion evenly shaded in green, indicating an elasticity score of 1. A US-guided core biopsy revealed an atypical ductal 
hyperplasia, which was confirmed to be a low grade ductal carcinoma in situ by subsequent excision (case 1 on Table 2). 
A B
Fig. 3. A 39-year-old woman with a Breast Imaging Reporting and Data System (BI-RADS) category 3 lesion on supplemental screening 
ultrasonography. 
A. Transverse B-mode ultrasonogram shows a 12-mm, oval, indistinct mass (arrows). B. Ultrasound (US) elastographic image shows the entire 
mass shaded in blue, indicating an elasticity score of 5. A US-guided core biopsy revealed an atypical ductal hyperplasia involving papilloma, 
which was confirmed to be a low grade ductal carcinoma in situ by subsequent excision (case 2 on Table 2). 
A BUS Elastography for BI-RADS Category 3 Lesions
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been verification bias, as 20.5% (56 of 273) of the benign lesions 
were followed for less than 24 months. Second, there may have 
been selection bias, as we included BI-RADS category 3 lesions, 
which were scheduled for US-guided core biopsy. Therefore, 
an unidentified family history or other risk factors motivating 
patients opting to undergo biopsy might have increased the rate 
of malignancy in our study group. In addition, the generalizability 
of our results to the entire spectrum of BI-RADS category 3 lesions 
encountered in daily practice is limited due to this selection bias. 
Third, this was a non-randomized study from a single institution. 
In addition, US elastography and B-mode ultrasonography images 
could not be evaluated in a completely independent manner, which 
might have affected the categorization of each finding.
In conclusion, US elastography has the potential to reduce the 
number of BI-RADS category 3 lesions on ultrasonography by 
allowing them to be downgraded from BI-RADS category 3 to 
category 2 when they show a negative elasticity score. 
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